Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes

International Journal of Cancer

Volumn 106, Issue 5, 2003, Pages 752-757

  Jiang, Wen G ^a   Douglas Jones, Anthony ^a   Mansel, Robert E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Metastasis; Peroxisome proliferator activated receptor gamma; PPAR co activator; Prognosis

Indexed keywords

CELL NUCLEUS RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; RETINOIC ACID; STEROID; TRANSCRIPTION FACTOR; UVOMORULIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER PATIENT; COHORT ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIGENE FAMILY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN FAMILY; PROTO ONCOGENE; TRANSCRIPTION REGULATION; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELLS, CULTURED; DNA PRIMERS; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0042524273     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11302     Document Type: Article

References (48)

1. Alvares K, Carrillo A, Yuan PM, Kawano H, Morimoto RI, Reddy JK. Identification of cytosolic peroxisome proliferator binding-protein as a member of the heat-shock protein hsp70 family. Proc Natl Acad Sci USA 1990;87:5293-7.
2. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347: 645-9.
3. Beck F, Plummer S, Senior PV, et al. The ontogeny of peroxisome-proliferator-activated receptor gene-expression in the mouse and rat. Proc R Soc Lond 1992;247:83-7.
4. Zhang BW, Marcus SL, Sajjadi FG, Alvares K, Reddy JK, Subramani S, Rachubinski RA, Capone JP. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-coa hydratase 3-hydroxyacyl-coa dehydrogenase. Proc Natl Acad Sci USA 1992;89:7541-5.
5. Forman BM, Chen J, Evans RM. Hydropipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator activated receptors α and δ. Proc Natl Acad Sci USA 1997;94: 4312-7.
6. Kliewer SA, Sundeth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator activated receptor α and γ. Proc Natl Acad Sci USA 1997;94:4318-23.
7. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129-38.
8. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-5.
9. Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002;95:2243-51.
10. Ohta T, Elnemr A, Yamamoto M, Ninomiya I, Fushida S, Nishimura GI, Fujimura T, Kitagawa H, Kayahara M, Shimizu K, Yi SQ, Miwa K. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 2002;21:37-42.
11. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-8.
12. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, et al. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001;61:497-503.
13. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001;61: 2424-8.
14. Kohno H, Yoshitani S, Takashima S, Okumura A, Hosokawa M, Yamaguchi N, Tanaka T. Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res 2001;92:396-403.
15. Wang CG, Fu MF, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VKK, Lazar MA, Pestell RG. Inhibition of cellular proliferation through I kappa B kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 2001;21:3057-70.
16. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
17. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MAK, Fukuda R, Nagasue N, Kinoshita Y. Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPAR gamma agonists. Br J Cancer 2000;83:1394-400.
18. Hisatake J, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000;60:5494-8.
19. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000;97: 10990-5.
20. Kitamura S, Miyazaki Y, Hiraoka S, Toyota M, Nagasawa Y, Kondo S, Kiyohara T, Shinomura Y, Matsuzawa Y. PPAR gamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. Biochem Biophys Res Commun 1999;265:453-6.
21. Puigserver P, Wu ZD, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-39.
22. Castillo G, Brun RP, Rosenfield JK, Hauser S, Park CW, Troy AE, Wright ME, Spiegelman BM. An adipogenic cofactor bound by the differentiation domain of PPAR gamma. EMBO J 1999;18:3676-587.
23. Puigserver P, Adelmant C, Wu ZD, Fan M, Xu JM, O'Malley B, Spiegelman BM. Activation of PPAR gamma coactivator-1 through transcription factor docking. Science 1999;286:1368-71.
24. Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN. Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res 2000;6:3241-8.
25. Jiang WG, Redfern A, Bryce RP, Mansel RE. Peroxisome proliferator activated receptor-gamma (PPAR-γ) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000;62:119-27.
26. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000;272:380-5.
27. Thoennes SR, Tate PL, Price TM, Kilgore MW. Differential transcriptional activation of peroxisome prolilferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol Cell Endocrinol 2000;160:67-73.
28. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MCA. Regulation of the expression of E-cadherin on human cancer cells by gamma linolenic acid. Cancer Res 1995;55:5043-8.
29. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Scott C, Puntis MCA. Inhibition of invasion and motility of human colon cancer cells by γ linolenic acid. Br J Cancer 1995;71:744-52.
30. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92:418-23.
31. Suh N, Wang YP, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
32. Yee LD, Sabourin CLK, Liu L, Li HM, Smith PJ, Seewaldt V, Kniss DA. Peroxisome proliferator-activated receptor gamma activation in human breast cancer. Int J Oncol 1999;15:967-73.
33. Wang X, Kilgore MW. Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gaminal in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol 2002;194:123-32.
34. Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A. The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 2001;114: 4117-26.
35. Esterbauer H, Oberkofler H, Krempler F, Patsch W. Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 1999;62:98-102.
36. Larrouy D, Vidal H, Andreelli F, Laville M, Langin D. Cloning and mRNA tissue distribution of human PPA gamma coactivator-1. Int J Obes Relat Metab Disord 1999;23:1327-32.,
37. Cunnick G, Jiang WG, Gomez KF, Mansel RE. Quantitation of lymphangiogenesis using real time quantitative PCR and breast cancer as a model. Biochem Biophys Res Commun 2001;288:1143-6.
38. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator activated receptor-γ and levels of prostaglandin E2 and 15-deoxy-delta-12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003;103:84-90.
39. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPAR gamma agonists are mediated via upregulation of PTEN. Curr Biol 2001;11: 764-8.
40. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7.
41. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-32.
42. Catzavelos C, Bhatacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, MoravaProtzner I, Kapusta L, Franssen E, Pritchard KI, et al. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
43. Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R. P27(Kip1) expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000;89:236-41.
44. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Pathol 1996;105:394-402.
45. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-8.
46. Seshadri R, Lee CSL, Hui R, McCaul K, Horsfall DJ, Sutherland RL. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 1996;2: 1177-84.
47. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 2002;44:2220-6.
48. Badwari-AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator activated receptor-gamma. Int J Cancer 2002;20:1109-22.